Impact on liver position under breath-hold by computed tomography contrast agents in stereotactic body radiotherapy of liver cancer.

Miura, Hideharu; Ozawa, Shuichi; Nakao, Minoru; Doi, Yoshiko; Kubo, Katsumaro; Kenjo, Masahiro; Nagata, Yasushi

Miura, Hideharu; Ozawa, Shuichi; Nakao, Minoru; Doi, Yoshiko; Kubo, Katsumaro; Kenjo, Masahiro; Nagata, Yasushi.

Afiliación

Miura H; Hiroshima High-Precision Radiotherapy Cancer Center, Hiroshima, Japan.
Ozawa S; Department of Radiation Oncology, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Nakao M; Hiroshima High-Precision Radiotherapy Cancer Center, Hiroshima, Japan.
Doi Y; Department of Radiation Oncology, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Kubo K; Hiroshima High-Precision Radiotherapy Cancer Center, Hiroshima, Japan.
Kenjo M; Department of Radiation Oncology, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Nagata Y; Hiroshima High-Precision Radiotherapy Cancer Center, Hiroshima, Japan.

Rep Pract Oncol Radiother ; 26(6): 1035-1044, 2021.

Article en En | MEDLINE | ID: mdl-34992878

Palabras clave

contrast enhancement agent; image-guided radiotherapy; inter-fraction liver position; intra-fraction liver position; liver cancer radiotherapy; stereotactic body radiotherapy

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Observational_studies Idioma: En Revista: Rep Pract Oncol Radiother Año: 2021 Tipo del documento: Article País de afiliación: Japón

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google